[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356402-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356402-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","preclinical-assessment-of-hla-a0201-restricted-psma-and-steap1-epitopes-for-peptide-based-immunotherapy-in-prostate-cancer","Preclinical Assessment of HLA-A*02:01-Restricted PSMA and STEAP1 Epitopes for Peptide-Based Immunotherapy in Prostate Cancer","","Peptide-based immunotherapy targeting tumor-associated antigens is evaluated for prostate cancer using a preclinical pipeline to assess immunogenic epitope candidates from STEAP1 and PSMA. High-affinity cytotoxic T lymphocyte epitopes restricted to HLA-A*02:01 are predicted and tested for antigenicity, conservation, and proteasomal processing, followed by molecular docking and peptide synthesis. In vitro validation employs ELISA MHC binding, IFN-γ ELISpot, and intracellular cytokine staining with splenocytes from HLA-A*02:01 transgenic mice. Four peptides show strong HLA-A*02:01 binding and T cell activation, with P3 the most potent candidate, supporting further development.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/preclinical-assessment-of-hla-a0201-restricted-psma-and-steap1-epitopes-for-peptide-based-immunotherapy-in-prostate-cancer/356402/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/preclinical-assessment-of-hla-a0201-restricted-psma-and-steap1-epitopes-for-peptide-based-immunotherapy-in-prostate-cancer/356402.png","ImageObject",300,407,{"name":42,"@type":43},"Asher","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-08","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Which epitopes and antigen targets are assessed in this preclinical study?","Question",{"text":63,"@type":64},"The study evaluates CTL epitope candidates derived from STEAP1 and PSMA that are restricted to HLA-A*02:01 for prostate cancer immunotherapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How are peptide candidates evaluated for MHC binding and immunogenicity?",{"text":68,"@type":64},"Predicted epitopes are assessed for antigenicity, conservation, and proteasomal processing, with molecular docking to HLA-A*02:01. Experimental validation uses ELISA-based MHC binding, IFN-γ ELISpot, and intracellular cytokine staining with transgenic mouse splenocytes.",{"name":70,"@type":61,"acceptedAnswer":71},"What is the main finding regarding the potency of the selected peptides?",{"text":72,"@type":64},"Four peptides (P1–P4) demonstrate strong HLA-A*02:01 binding and compatibility with the MHC class I groove, while ELISpot and ICS confirm CD8+ T cell activation and polyfunctional cytokine expression. Nano-immunogenicity profiling identifies P3 as the most potent candidate.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356402,1790135773,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Drug Design, Development and Therapy  \n Open Access Full Text Article  \nORIGINAL RESEARCH  \nPreclinical Assessment of HLA-A*02:01-Restricted PSMA and STEAP1 Epitopes for Peptide-Based Immunotherapy in Prostate Cancer  \nYueting Huang 1 , *, Yang Yang2 , *, Yanni Xie 1 , *, Yue Shu2 , Siqi Yang2 , Xuezhi Long 1 , Zhipeng Wen 1 , Xiaolu Duan 1 , Li Fu2 , *, Di Gu 1 , Tuxiong Huang 1  \n1Guangdong Provincial Key Laboratory of Urological Diseases, Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, People’s Republic of China; 2Guangdong Provincial Key Laboratory of Regional Immunity and Diseases, Department of Pharmacology and International Cancer Center, Shenzhen University Medical School, Shenzhen, Guangdong, People’s Republic of China  \n*These authors contributed equally to this work  \nCorrespondence: Tuxiong Huang; Di Gu, Email [tuxionghuang@163.com](tuxionghuang@163.com); [sveong@163.com](sveong@163.com)  \n\n| Background: Peptide-based immunotherapy targeting tumor-associated antigens presents a promising approach for prostate cancer intervention. In this study, we employed a preclinical approach to evaluate immunogenic epitope candidates derived from STEAP1 and PSMA, two well-characterized prostate cancer-associated antigens.\u003Cbr>Methods: High-affinity cytotoxic T lymphocyte (CTL) epitopes restricted to HLA-A*02:01 were predicted and evaluated for antigenicity, conservation, and proteasomal processing. Molecular docking with HLA-A*02:01 was performed and peptides were synthesized for experimental validation. In-vitro assays including ELISA-based MHC binding, IFN-γ ELISpot, and intracellular cytokine staining (ICS) were conducted using splenocytes isolated from HLA-A*02:01 transgenic mice.\u003Cbr>Results: Four peptides (P1, P2, P3 and P4), demonstrated strong binding to HLA-A*02:01 in-silico and were structurally compatible with the MHC class I groove. ELISA confirmed high binding for P3 and P1 at lower concentrations, while P2 and P4 showed moderate affinity. ELISpot assays showed robust IFN-γ responses in peptide-stimulated splenocytes, particularly for P3 and P1 . ICS confirmed CD8+ T cell activation and polyfunctional cytokine expression. A comparative Nano-immunogenicity profile revealed P3 as the most potent candidate.\u003Cbr>Conclusion: This study provides preclinical evidence of antigenicity and MHC-I compatibility of four prostate cancer-derived CTLepitopes using a transgenic mouse model. These findings support the advancement of these peptides as candidates for peptide-based immunotherapy in prostate cancer.\u003Cbr>Keywords: cytotoxic T lymphocyte, epitope, HLA-A*02:01, peptide-based immunotherapy, prostate cancer |\n| --- |\n| Introduction\u003Cbr>Prostate cancer (PC) remains a major global health concern, ranking as the second most frequently diagnosed malignancy and the fifth leading cause of cancer-related deaths among men worldwide. As per GLOBOCAN 2020 data, over 1.4 million new PC cases were reported globally, with annual mortality surpassing 375,000 .1,2 The incidence is projected to rise, particularly in low- and middle-income countries, due to demographic shifts, sedentary lifestyles, and evolving dietary patterns. While localized prostate cancer is often manageable through curative interventions like radical prostatectomy and radiation, the emergence of metastatic and castration-resistant prostate cancer (CRPC) presentsa formidable therapeutic challenge.3,4 Despite recent advancements in systemic treatments such as taxeme-based chemotherapy and androgen receptor-targeting agents resistance and disease progression remain inevitable in most patients.5 Against this backdrop, cancer immunotherapy has emerged as a potent strategy capable of restoring and enhancing immune surveillance against tumors. Among various approaches, peptide-based vaccines represent a rational |\n\n[https://doi.org/10.2147/DDDT.S576346](https://doi.org/10.2147/DDDT.S576346)  \n[Received: 12 November 2025](","cbCaihIxi06J26bE","https://ap.wps.com/l/cbCaihIxi06J26bE","pdf",7997082,17,"English","# Background\n# Methods\n# Results\n# Conclusion","[{\"question\":\"Which epitopes and antigen targets are assessed in this preclinical study?\",\"answer\":\"The study evaluates CTL epitope candidates derived from STEAP1 and PSMA that are restricted to HLA-A*02:01 for prostate cancer immunotherapy.\"},{\"question\":\"How are peptide candidates evaluated for MHC binding and immunogenicity?\",\"answer\":\"Predicted epitopes are assessed for antigenicity, conservation, and proteasomal processing, with molecular docking to HLA-A*02:01. Experimental validation uses ELISA-based MHC binding, IFN-γ ELISpot, and intracellular cytokine staining with transgenic mouse splenocytes.\"},{\"question\":\"What is the main finding regarding the potency of the selected peptides?\",\"answer\":\"Four peptides (P1–P4) demonstrate strong HLA-A*02:01 binding and compatibility with the MHC class I groove, while ELISpot and ICS confirm CD8+ T cell activation and polyfunctional cytokine expression. Nano-immunogenicity profiling identifies P3 as the most potent candidate.\"}]","Preclinical Assessment of HLA-A*02:01-Restricted PSMA and STEAP1 Epitopes for Peptide-Based Immunotherapy in Prostate Cancer | PDF",1790125203,43,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5d3a35393183d6ad7e92e969108ea7fa.webp",983,1272,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/50398a67560e83fdda7e6242f71c2639.webp",982,1270,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ff04094b8dcceff066e91a189035091d.webp",981,1269,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d959d56ca77b6da2a5263254a71956be.webp",980,1268]